






HOFFMANN EITLE



Life Science IP Seminar 2024

June 25-27, 2024
Invitation & Program

Invitation – Life Science IP Seminar 2024

Dear Colleagues and Friends,

We invite you to join us in Munich this summer for our Life Science IP Seminar! We are happy to be able to invite you back in person after a longer period where this was not possible due to COVID and other constraints. Although the online events we hosted in the meantime were well received, we are really looking forward to meeting all of you again in person.

As usual, our seminar is aimed at an audience with substantial prior knowledge of patents and IP in the life sciences and pharma area. Generally, the topics we will focus on this year include:

- EPO case law and best practice
- First experiences with the UPC
- SPCs – case law and future developments
- Litigation topics and EU competition law
- AI in the world of pharma

The speakers will primarily be experienced practitioners from our firm, who will be joined by external guest speakers who have a high level of expertise in their areas.

In addition to the educational aspect of the seminar, there will of course also be time for networking and getting to know the other participants. We have organised an evening trip on the second day to the Lenbachhaus Art Museum, with a private guided tour outside normal opening hours, followed by dinner and drinks at the museum.

More details about the event can be found on the following pages. Please note that we offer a greatly reduced rate for in-house attendees and that we also offer an early-bird discount until April 5th. If you are interested in attending, please do register soon.

We very much look forward to welcoming you in Munich this summer!

Daniel Grohs & Morten Garberg

Seminar Chairmen

Location

HOFFMANN EITLE Conference Centre
Arabellastraße 30, 81925 Munich

Contact for event

HOFFMANN EITLE
Paulina Szwarc, pszwarc@hoffmanneitle.com

Language

English

Dates

June 25 - 27, 2024

— Conference starts: 13:00 on 25 June

— Conference concludes: 15:45 on 27 June

Attendance fee

The fee covers seminar attendance, course notes, lunch, reception and the social outing

| | In-house / general counsel | Private practice |
|---|-------------------------------|---------------------|
| Early bird rate until April 5, 2024 | €450 + VAT | €950 + VAT |
| Standard rate until May 17, 2024 | €550 + VAT | €1050 + VAT |

Registration deadline

Please register as soon as possible and **no later than May 17, 2024**. Early booking is particularly appreciated to secure adequate space.

Accommodation

Please note that we are not organizing hotel arrangements for participants. However, we are more than happy to offer suggestions and recommendations to assist you in finding suitable accommodations nearby.

Seminar schedule

Day 1 (Tuesday 25 June)

- G2/21 and follow-up case law: post-published data for inventive step at the EPO
- Artificial intelligence and other digital technologies in the life sciences: Legal challenges for IP
- G1/23 – New referral on public prior use
- 10x Genomics vs Nanostrings – first clues on how the UPC will look at validity and preliminary injunction requirements
- SPC – case law update

Day 2 (Wednesday 26 June)

- UPC – panel discussion
- Bolar exemptions
- AI in drug discovery
- Sufficiency of disclosure – case law developments at the EPO
- What level of significance is needed for data to credibly show an effect at the EPO?
- Clinical trial publications as prior art at the EPO
- Interplay between EU competition law and patents – recent developments at the European Commission
- Rules of Procedures of the Boards of Appeal – an update

Day 3 (Thursday 27 June)

- Discovery during litigation in the US, UK & UPC – and how to use it in other jurisdictions
- Pharma inventions: at what stage of development should you file & drafting tips
- SPC – future developments
- Doctrine of equivalence and impact of adaptation
- Public access to documents filed with courts and regulatory authorities – current status quo
- Antibodies – EPO approach to patentability